Reaction
Eosinophilic Oesophagitis reporting signals
As of the last recalculation, Eosinophilic Oesophagitis appears in 2,554 FAERS reports alongside 17 co-occurring drug terms. The strongest observed disproportionality signal is DUPILUMAB (PRR 106.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Dupilumab | 1,830 | 106.7 | 107.1 |
| Ciclesonide | 21 | 12.7 | 12.7 |
| Budesonide | 82 | 11.7 | 11.7 |
| Guanfacine | 9 | 9.4 | 9.4 |
| Hydroxyzine Hydrochloride | 13 | 8.1 | 8.1 |
| Hydroxyzine Hydrochloride Oral | 13 | 8.1 | 8.1 |
| Dicyclomine Hydrochloride | 12 | 6.9 | 6.9 |
| Buspirone Hydrochloride | 9 | 6.7 | 6.7 |
| Mepolizumab | 35 | 5.8 | 5.8 |
| Fexofenadine Hydrochloride | 15 | 5.7 | 5.7 |
| Cetirizine Hcl | 6 | 5.3 | 5.3 |
| Omalizumab | 47 | 4.6 | 4.6 |
| Benralizumab | 10 | 4.1 | 4.1 |
| Levocetirizine Dihydrochloride | 12 | 4.1 | 4.1 |
| Lisdexamfetamine Dimesylate | 14 | 3.5 | 3.5 |
| Dronedarone | 4 | 3.2 | 3.2 |
| Fremanezumab-Vfrm | 3 | 2.1 | 2.1 |